Get started

Financials · ATRA

Atara Biotherapeutics Inc. (ATRA) financials

For the twelve months ended Jun 30, 2026, Atara Biotherapeutics Inc. reported $6.19M of revenue and -$16.69M of net income.

Revenue, TTM
$6.19M
Revenue growth, YoY
-96.7%
Net income, TTM
-$16.69M
Net margin
-269.4%
EPS, diluted, TTM
-$1.73
Cash
$3.22M
P/S
13.26
Market cap
$82.1M
Annual revenue$120.77M
FY2022FY2025
Annual net income$32.69M
FY2016FY2025
Annual free cash flow-$50.94M
FY2016FY2025

ATRA revenue and earnings growth

ATRA revenueQ2 2026$630.0K

Quarter YoY
-96.4%
QoQ
+22.1%
FY YoY
-6.3%

ATRA revenue was $630.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 96.4% from a year earlier and up 22.1% from the prior quarter. For the full fiscal 2025 it was $120.77M, down 6.3% from fiscal 2024. It rose in 1 of the last 3 fiscal years.

ATRA net incomeQ2 2026-$4.83M

ATRA net income was -$4.83M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $2.39M a year earlier. For the full fiscal 2025 it was $32.69M, compared with -$85.40M in fiscal 2024. Fiscal 2025 is the highest of the 13 fiscal years on file.

ATRA EPSQ2 2026-$0.32

ATRA diluted EPS was -$0.32 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.19 a year earlier. For the full fiscal 2025 it was $2.57.

ATRA free cash flowQ4 2025-$5.70M

ATRA free cash flow was -$5.70M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$24.56M a year earlier. For the full fiscal 2025 it was -$50.94M, compared with -$68.96M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$120.77M$128.94M$8.57M$63.57M------
Research and development$37.45M$151.48M$224.78M$272.53M$282.00M$244.65M$216.10M$167.46M$81.21M$56.51M
Selling, general and admin$26.25M$39.89M$50.91M$71.55M$78.80M$64.40M$79.58M$69.65M$40.33M$24.73M
Operating income$35.86M-$83.44M-$276.01M-$280.51M-$340.46M-$309.05M-$295.68M-$237.11M-$121.53M-$81.24M
Interest expense$3.79M$4.62M$5.29M$373.0K------
Pre-tax income$32.72M-$85.42M-$276.11M-$228.29M-$340.10M-$306.61M-$290.96M-$230.74M-$119.50M-$79.04M
Income tax$31.0K-$12.0K$15.0K$12.0K$46.0K$15.0K$12.0K-$44.0K-$14.0K$10.0K
Net income$32.69M-$85.40M-$276.13M-$228.30M-$340.14M-$306.62M-$290.98M-$230.70M-$119.49M-$79.05M
EPS, basic$2.61-$11.41-$65.19-$56.00-$90.75-$103.75-$141.75-$131.75-$100.00-$68.75
EPS, diluted$2.57-$11.41-$65.19-$56.00-$90.75-$103.75-$141.75-$131.75-$100.00-$68.75
Diluted shares12.7M7.5M4.2M4.1M3.7M3.0M2.1M1.8M1.2M1.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$8.48M$25.18M$25.99M$93.09M$107.48M$201.80M$75.71M$62.09M$80.62M$48.16M
Short-term investments$0$17.47M$25.88M$149.88M$264.98M$300.25M$184.79M$248.93M$86.87M$207.71M
Receivables$1.25M$1.48M$34.11M$40.22M$986.0K$1.25M$0---
Inventory$0$10.65M$9.71M$1.59M$0-----
Current assets$12.21M$64.89M$101.87M$295.08M$384.62M$523.27M$272.99M$321.49M$172.19M$260.55M
Total assets$20.23M$109.10M$165.50M$376.42M$468.13M$588.12M$342.94M$391.84M$217.78M$263.91M
Current liabilities$14.92M$134.57M$142.23M$78.92M$105.79M$82.90M$36.74M$39.98M$27.65M$9.68M
Total liabilities$58.74M$206.38M$264.74M$249.78M$188.51M$125.78M$52.16M$52.98M$39.91M$10.18M
Shareholders' equity-$38.50M-$97.28M$99.23M$126.64M$279.61M$462.34M$290.78M$339.22M$177.86M$253.74M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$50.94M-$68.72M-$192.98M-$270.43M-$220.52M-$180.76M-$235.63M-$179.77M-$87.50M-$60.02M
Capital expenditures$0$246.0K$1.22M$4.19M$10.58M$4.51M$5.73M$35.92M$20.23M$3.02M
Free cash flow-$50.94M-$68.96M-$194.20M-$274.62M-$231.10M-$185.27M-$241.36M-$215.70M-$107.73M-$63.05M
Investing cash flow$18.15M$8.62M$123.87M$202.96M$22.26M-$120.73M$60.46M-$196.29M$99.91M$83.74M
Financing cash flow$16.10M$59.28M$2.01M$53.08M$103.94M$427.57M$188.79M$357.54M$20.05M$506.0K
Stock-based compensation$9.75M$27.00M$45.39M$53.84M$53.87M$51.35M$51.70M$33.82M$23.10M$16.78M
Depreciation and amortization$2.12M$5.05M$4.83M$5.65M$9.35M$8.33M$7.07M$3.73M$956.0K$383.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-6.3%1404.0%-86.5%-------
Operating margin29.7%-64.7%-3219.5%-441.2%------
Net margin27.1%-66.2%-3220.9%-359.1%------
Free cash flow margin-42.2%-53.5%-2265.3%-432.0%------
Return on equity---278.3%-180.3%-121.6%-66.3%-100.1%-68.0%-67.2%-31.2%
Return on assets161.5%-78.3%-166.8%-60.7%-72.7%-52.1%-84.8%-58.9%-54.9%-30.0%
Current ratio0.820.480.723.743.646.317.438.046.2326.93

Source: XBRL data Atara Biotherapeutics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Aug 12, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ATRA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ATRA$6.19M-96.7%-$16.69M-269.4%$82.1M
IOVA$378.98M+51.3%-$220.53M-58.2%$3.78B
ALLO$6.94M+269.5%-$174.46M-2513.9%$366.2M
SABS$0-100.0%$13.27M-$279.3M

ATRA FAQ

7 questions
  • What is ATRA revenue?
    Atara Biotherapeutics Inc. (ATRA) reported $6.19M of revenue for the twelve months ended Jun 30, 2026. That is down 96.7% from the year before. Revenue for fiscal 2025 was $120.77M.
  • Is ATRA profitable?
    No. Atara Biotherapeutics Inc. reported a net loss of $16.69M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ATRA have?
    Atara Biotherapeutics Inc. reported $3.22M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ATRA revenue growing?
    Atara Biotherapeutics Inc.'s revenue changed -6.3% in fiscal 2025, to $120.77M.
  • What is ATRA earnings per share?
    Diluted earnings per share were -$1.73 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ATRA last report financial results?
    The latest statements here come from Atara Biotherapeutics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this ATRA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Atara Biotherapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.